VER Share PerformanceMore
|52 week high||35.000 29/12/16|
|52 week low||7.250 14/12/17|
|52 week change||-24.765 (-74.20%)|
|4 week volume||17,958,666 18/11/17|
Latest News« previous» nextMore
14/12/2017 - 13:15 RNS
RNS Number: 2977Z Vernalis PLC 14 December 2017 14 December 2017 LSE: VER Vernalis Results of Annual General Meeting Resolutions Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed. All resolutions were approved on a show of hands. The number of proxy votes received...
14/12/2017 - 08:49 StockMarketWire
Prescriptions of Vernalis' cough cold syrup Tuzistra XR continue to grow steadily, up 85% in the 22 weeks to 1 December. H...
14/12/2017 - 07:00 RNS
RNS Number: 2975Z Vernalis PLC 14 December 2017 14 December 2017 LSE: VER AGM Statement Tuzistra XR prescriptions continue to grow steadily, despite a reduction in narcotic prescribing Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & B...
13/12/2017 - 08:02 StockMarketWire
Vernalis has entered into a drug discovery collaboration with Daiichi Sankyo Company which will utilizing Vernalis' frag...
13/12/2017 - 07:00 RNS
RNS Number: 1386Z Vernalis PLC 13 December 2017 13 December 2017 LSE: VER Vernalis plc enters into research collaboration with Daiichi Sankyo Vernalis plc (LSE: VER) announced today that it has entered into a drug discovery collaboration with Daiichi Sankyo Company, Limited utilizing Vernalis' fragment and structure-based drug discovery platform again...
06/12/2017 - 09:36 StockMarketWire
Vernalis has received a milestone payment from partner Servier after they achieved pre-clinical progress in their third on...
06/12/2017 - 07:00 RNS
RNS Number: 4885Y Vernalis PLC 06 December 2017 6 December 2017 LSE: VER Vernalis and Servier Achieve Research Milestone in Third Oncology Collaboration Vernalis plc and Servier today announce the achievement of a pre-clinical milestone in their third oncology drug discovery collaboration. Vernalis will receive a payment of 1.0m from Servier in recogn...
05/12/2017 - 16:40 RNS
RNS Number: 4755Y Vernalis PLC 05 December 2017 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined percen...
|Dividend yield||0 %|
Latest discussion posts More
“It's been a long one ( since mid Aug 2016 ) now . Whilst trend wise it's obviously only going one way I think we may find a bottom here . So my risk reward view of ...”▼
“Remember my post back in April ? Not many here since . Chart don't lie , it didn't then it isn't now . Though it may be basing . Or about to . In other words we ...”▼
“Recent RNS from Vernalis: "Total revenues are expected to be ahead of current market expectations, principally as a result of larger than expected research collaboration ...”▼
Codes & Symbols
|Symbols||VER, LSE:VER, VER.L, VER:LN, LON:VER, XLON:VER|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment